Literature DB >> 12020398

Positron emission tomography and sentinel lymph node dissection in breast cancer.

Pond R Kelemen1, Val Lowe, Nancy Phillips.   

Abstract

Sentinel lymph node dissection (SLND) is emerging as the preferred method of axillary staging for breast cancer patients. To further the use of noninvasive techniques in breast cancer, positron emission tomography (PET) scans have been considered as an alternative axillary staging modality. In order to compare the 2 modalities, we studied 15 invasive breast cancer patients who had undergone a preoperative PET scan before sentinel lymphadenectomy. PET scans were compared to axillary pathology results, which were defined as the greatest diameter of nodal metastases. Primary tumor sizes ranged from 0.5 cm to 5.0 cm (median,1.5 cm) and all were ductal in origin except for 1 invasive lobular and 1 mucinous carcinoma. Ten women had completion axillary dissections. Sentinel lymph node dissection was successful in all patients with completion dissections and no false-negative results. Five patients had sentinel node metastases, but PET scans identified only 1 of these patients, resulting in 4 false-negative PET scans. Missed metastases ranged in size from a micrometastatic focus identified only by immunohistochemistry to a nodal tumor measuring 11 mm in diameter. In addition, 1 woman with a PET-positive axilla was tumor free by SLND and remains free of axillary recurrence 29 months postoperatively. Two women had mediastinal uptake by PET scanning and were found to be tumor free after computerized tomography. The results of this preliminary study suggest that PET scanning using current techniques can be used as an adjunct to SLND rather than as an alternative staging technique.

Entities:  

Mesh:

Year:  2002        PMID: 12020398     DOI: 10.3816/CBC.2002.n.014

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  7 in total

1.  The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.

Authors:  W H Choi; I R Yoo; J H O; S H Kim; S K Chung
Journal:  Br J Radiol       Date:  2010-11-16       Impact factor: 3.039

Review 2.  A systematic review of FDG-PET in breast cancer.

Authors:  S Escalona; J A Blasco; M M Reza; E Andradas; N Gómez
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

Review 3.  FDG-PET for axillary lymph node staging in primary breast cancer.

Authors:  Flavio Crippa; Alberto Gerali; Alessandra Alessi; Roberto Agresti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

4.  Unusual Contralateral Axillary Lymph Node Metastasis in a Second Primary Breast Cancer Detected by FDG PET/CT and Lymphoscintigraphy.

Authors:  Ji-Young Kim; Hyunjong Lee; Tae Sung Kim; Han-Sung Kang; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2017-08-11

5.  Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.

Authors:  Manabu Futamura; Takahiko Asano; Kazuhiro Kobayashi; Kasumi Morimitsu; Masahito Nawa; Masako Kanematsu; Akemi Morikawa; Ryutaro Mori; Kazuhiro Yoshida
Journal:  World J Surg Oncol       Date:  2015-02-14       Impact factor: 2.754

6.  Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.

Authors:  L Bazzola; C Foroni; D Andreis; V Zanoni; M R Cappelletti; G Allevi; S Aguggini; C Strina; M Milani; S Venturini; F Ferrozzi; R Giardini; R Bertoni; H Turley; K Gatter; P G Petronini; S B Fox; A L Harris; M Martinotti; A Berruti; A Bottini; A R Reynolds; D Generali
Journal:  Br J Cancer       Date:  2014-12-02       Impact factor: 7.640

7.  Diagnostic Performance of FDG-PET/CT Scan as Compared to US-Guided FNA in Prediction of Axillary Lymph Node Involvement in Breast Cancer Patients.

Authors:  Hazem I Assi; Ibrahim A Alameh; Jessica Khoury; Maroun Bou Zerdan; Vanessa Akiki; Maya Charafeddine; Ghida I El Saheb; Fares Sukhon; Eman Sbaity; Serine Baydoun; Nina Shabb; Ghina Berjawi; Mohamad B Haidar
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.